Compounded DSIP

Honestly, the evidence is limited and mixed. Some older studies in volunteers and insomnia patients reported improved sleep quality and continuity, while a double-blind trial concluded short-term DSIP was unlikely to offer major benefit for chronic insomnia. The peptide’s link to sleep has never been definitively confirmed. We treat DSIP as an investigational trial: it may support sleep for some people, but it is not a proven therapy and may do nothing.

No. DSIP is not an FDA-approved drug and has no approved indication for sleep, stress, or any other use. It is offered only as a compounded, off-label, investigational option prescribed at a licensed physician’s discretion. We will never claim it is proven or approved.

Proposed mechanisms include modulating slow-wave (delta) sleep activity, influencing the HPA stress axis and cortisol dynamics, and possibly affecting circadian rhythms. None of these is fully established — DSIP’s receptor and signaling pathway have never been definitively identified, so its mechanism is genuinely not fully understood.

If DSIP is going to help with sleep, users typically report it within the first few weeks. Because effects are inconsistent across studies, many doctors structure it as a short trial: if there is no clear, sustained benefit after several weeks, it is discontinued rather than continued indefinitely.

DSIP has been studied for modulation of the body’s stress-hormone (HPA) axis, including ACTH and cortisol. Some animal and human findings suggest a calming, stress-attenuating effect, but human results are inconsistent — one study found an effect on the adrenocortical axis and another found none. Any stress benefit should be considered possible, not proven.

DSIP is given as a small subcutaneous injection, usually 30–60 minutes before bed. There is no standardized, validated dosing protocol, so your prescribing doctor sets a conservative starting dose and adjusts based on your response. Doses should never be self-escalated.

Reported side effects in the older literature are generally mild, but long-term, rigorous safety data are sparse. That uncertainty is part of why DSIP is offered only under physician supervision and as a time-limited trial. Report any unexpected or worsening symptoms to your care team and stop use.

Peptide12 partners with state-licensed compounding pharmacies that hold state and federal licensure and undergo regular USP <797> sterility audits. Every batch is third-party tested for identity, potency, sterility, and endotoxin before release. Compounded DSIP is not FDA-approved as a finished drug product but is prepared from regulated active ingredients under individualized prescription.

No. Compounded, investigational peptides like DSIP are not covered by commercial insurance. Some patients use HSA or FSA funds; your care team can help you check eligibility and provide documentation if needed.